Spyre Therapeutics, Inc. — Director's Dealing 2017

Aug 25, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2017-08-22

Reporting Person: Schuchart Aaron (Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-22	Employee Stock Option (right to buy)	$3.1	A	10000	Acquired	2027-08-21	Common Stock (10000)	Direct

Footnotes

F1: The stock option vests and becomes exercisable as to 50% of the shares subject to the option on August 22, 2018, an additional 30% of the shares subject to the option on August 22, 2019, and the remaining 20% of the shares subject to the option on August 22, 2020, subject to the continuing employment of the Reporting Person on each vesting date.